FLT3 and acute myeloid leukemia: Although FLT3 inhibitors can improve remission rates of AML patients, up to 60% experience drug toxicity or acquired resistance mechanisms, such as point mutations in the tyrosine kinase domain (TKD) that render FLT3 inhibitors ineffective [5,6,7].